Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) disclosed that it repurchased 280,000 H-shares on 8 April 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 3.75 to HKD 3.79 per share, for a total consideration of HKD 1.06 million.

Following the transaction: • Issued shares excluding treasury stock declined by 0.0063 % to 4.47 billion. • Treasury shares increased to 49.77 million, while total issued shares remained unchanged at 4.52 billion. • The volume-weighted average repurchase price was HKD 3.7729 per share.

Buyback mandate utilisation: • The current mandate, approved on 27 May 2025, authorises the company to repurchase up to 451.56 million shares. • Including the latest purchase, cumulative repurchases under this mandate total 43.12 million shares, equivalent to 9.55 % of the shares outstanding on the mandate date.

Compliance and timing: • The board confirmed all regulatory requirements under Hong Kong’s Main Board Listing Rules were met. • A 30-day moratorium on new share issues or treasury share sales is in effect until 9 May 2026, in line with Rule 10.06(3)(a).